BIONANO GENOMICS 2026 Q2
Earnings Overview & AI Insights

Earnings Performance

Summary of Financial Performance: Bionano reported Q2 2026 revenue of $8.2 million, up 21% year over year and above guidance. Consumables were the main growth driver, with consumable revenue up 30% to $4.3 million, while other revenue rose 38% to $2.5 million and software revenue declined 16% to $1.4 million due to deferred deployments. Gross margin improved to a record 53% from 52% a year ago, reflecting better operational efficiency. Adjusted operating expenses were essentially flat year over year at $8.7 million. The company ended Q2 with $10.4 million in cash, cash equivalents, and available-for-sale securities, and fully retired its outstanding senior secured convertible debt.

Company Outlook & Strategy: Management raised the low end of full-year 2026 revenue guidance to $31 million to $33 million, implying 9% to 16% growth, and initiated Q3 2026 revenue guidance of $8.2 million to $8.6 million. The company emphasized a strategy focused on profitable growth through higher utilization of installed systems, clinical adoption of OGM, selective customer acquisition, expanded reimbursement support, and improved profitability. Management expects revenue growth to continue and believes the business is progressing toward adjusted EBITDA breakeven over time.

Key Industry Trends: The company highlighted accelerating global adoption of optical genome mapping, especially in clinical settings and in Europe. Reimbursement has improved, with two Category I CPT codes now covering major OGM applications in hematologic malignancies and constitutional genetic disorders. The evidence base for OGM is expanding through clinical publications, including strong results in T-ALL, reproductive health, and prenatal genetic disorders, which management sees as a leading indicator of broader adoption.

Operational Highlights: Flow cell sales reached a record 9.22 thousand units, up 27% year over year, with sales to existing customers up 24%. Installed OGM systems totaled 397, up 5% from last year. Management said demand continues to outpace manufacturing capacity, though backlog is being worked down. The company also highlighted positive reception for software and compute upgrades that can increase throughput without new hardware, growth in VIA adoption beyond OGM, and plans to launch the OGM expansion for the Ionic system in Q4 2026. The return of Dr. Alex Hastie as Chief Scientific Officer was framed as a strategic scientific leadership move.

Challenges & Risks: The main near-term constraint is manufacturing capacity, particularly for flow cells, which is limiting the ability to fully meet demand and is the reason management did not raise the top end of guidance. Software revenue softness was attributed to timing delays in customer deployments. The company also remains focused on improving profitability while managing a relatively limited cash position of $10.4 million, though cash runway is expected into at least Q1 2027.

Key Analyst Questions & Responses: An analyst asked why the company raised only the low end of 2026 guidance and not the high end. Management responded that flow cell manufacturing capacity is still constrained and the company remains in backlog, so they prefer not to raise the upper end until supply can reliably meet demand, which they hope to remedy by mid-to-late Q4. The analyst also noted that Q3 guidance appears roughly flat sequentially, reinforcing the view that supply limitations are capping near-term revenue acceleration.